Clovis Oncology, Inc. is a Boulder, Colorado-based biopharmaceutical company focused on acquiring, developing, and commercializing cancer treatments in the United States and Europe. Founded in 2009, the company markets Rubraca, a PARP inhibitor used for ovarian, fallopian tube, peritoneal, and prostate cancers. Clovis operates through subsidiaries in the U.K., Ireland, Germany, Italy, France, Spain, and the Netherlands. The company also develops FAP-2286, a targeted radionuclide therapy candidate, and maintains a global research and clinical network.
